Canton Strategic Holdings (CNTN) Convertible Debt (2020 - 2021)
Canton Strategic Holdings' (CNTN) quarterly Convertible Debt came in at $772899.0 in Q4 2021, down 39.94% YoY from $1.3 million in Q4 2020, and down 39.94% on a QoQ basis from $1.3 million in Q4 2020.
Powered by 
Analysis
Canton Strategic Holdings (CNTN) Convertible Debt (2020 - 2021) Analysis & Trends
Canton Strategic Holdings (CNTN) has 2 years of Convertible Debt data on file, last reported at $772899.0 in Q4 2021.
- Quarterly Convertible Debt fell 39.94% year-over-year to $772899.0 in Q4 2021, while the trailing twelve-month figure through Dec 2021 was $772899.0 (down 39.94% YoY) and the FY2021 annual result came in at $772899.0, down 39.94% from the prior year.
- Convertible Debt retreated to $772899.0 in Q4 2021, from $1.3 million in the prior quarter.
- In the past five years, Convertible Debt ranged from a high of $1.3 million in Q4 2020 to a low of $772899.0 in Q4 2021.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Canton Strategic Holdings | 493.37 Mn | 493.37 Mn | - |